Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023
16 May 2023 - 3:30PM
Business Wire
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic disorders,
today announces the publication of the meeting notice for the
Annual General Meeting, which will be held on June 21, 2023 at 9 am
CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de
Bonnel, 69003 LYON, France.
The meeting notice, the convening brochure, the 2022 Universal
Registration Document and the other documents and information
mentioned in Article R.22-10-23 of the French Commercial code will
be available to shareholders on the Company’s website at least 21
days before the Meeting at the following link:
https://www.poxelpharma.com/en_us/investors/shareholder-information/annual-general-meeting-documents
Shareholders may vote in person on the day of the Meeting, but
may also vote by mail or by proxy without attending the Meeting in
person, as follows:
- by mail using the voting form; or
- by giving proxy to the Chairman of the General Meeting or to
any other individual or legal entity.
The detailed procedures for participating remotely and sending
written questions beforehand are available in the meeting notice
n°58, which was published in the BALO (French legal gazette) dated
May 15, 2023.
The results and presentation for the 2023 Annual General Meeting
will be available on Poxel’s website www.poxelpharma.com in the
Investors/ Shareholder Information/ Annual General Meeting
Documents section after the Meeting.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its
primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is focused on the treatment of adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is marketed for the treatment of
type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to
receive royalties and sales-based payments. Poxel has a strategic
partnership with Sumitomo Pharma for Imeglimin in Japan, China, and
eleven other Asian countries. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230515005839/en/
Contacts - Investor relations / Media
Aurélie Bozza Investor Relations & Communication Senior
Director aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
NewCap Emmanuel Huynh or Arthur Rouillé poxel@newcap.eu +33 1 44
71 94 94
Poxel (EU:POXEL)
Historical Stock Chart
From Apr 2024 to May 2024
Poxel (EU:POXEL)
Historical Stock Chart
From May 2023 to May 2024